JNJ-78934804 vs mirikizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline

JNJ-78934804

Developed by Johnson & Johnson

Phase 3 in Ulcerative ColitisCo-antibody combination (guselkumab + golimumab, SC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2028 · NCT07577856 (registry estimate)

No aligned efficacy figure on record for this race.

mirikizumab · Omvoh

Marketed by Eli Lilly

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

NCT03524092 · Phase 3 · completed

Randomized (re-randomization of induction responders), double-blind, placebo-controlled, adequately powered (n=544 in the key comparison), hard composite clinical/endoscopic primary endpoint that was statistically significant in the favorable direction (p<0.001) — meeting the 'strong' definition's full test.

Next expected readout: May 2027 · NCT07186101 (registry estimate)

Reported efficacy

Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders): Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders) (Week 40): Maintenance Period: Miri IR - 200 mg Miri SC 49.9% (95% CI 44.7 to 55) vs Maintenance Period: Miri IR - PBO SC 25.1% (95% CI 18.8 to 31.5) (met)

Result source: NCT03524092

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointJNJ-78934804mirikizumab
Clinical remission (induction)—Trial running · NCT0757785624.2% vs 13.3%+10.9 vs placebo300 mg IV Q4W · wk 12 · n 868NCT03518086
3 other results
  • 11.5% vs 4.8% 600 mg IV Q4W · wk 12 · n 61 · Phase 2 · primary NCT02589665
  • 22.6% vs 4.8% 200 mg IV Q4W · wk 12 · n 62 · Phase 2 · primary NCT02589665
  • 15.9% vs 4.8% 50 mg IV Q4W · wk 12 · n 63 · Phase 2 · primary NCT02589665
Clinical remission (maintenance)—Trial running · NCT0757785649.9% vs 25.1%+24.8 vs placebo200 mg SC · wk 40 · n 365NCT03524092
Clinical response (induction)—Trial running · NCT0757785663.5% vs 42.2%+21.3 vs placebo300 mg IV Q4W · wk 12 · n 868NCT03518086
3 other results
  • 49.2% vs 20.6% 600 mg IV Q4W · wk 12 · n 61 · Phase 2 · secondary NCT02589665
  • 59.7% vs 20.6% 200 mg IV Q4W · wk 12 · n 62 · Phase 2 · secondary NCT02589665
  • 41.3% vs 20.6% 50 mg IV Q4W · wk 12 · n 63 · Phase 2 · secondary NCT02589665
Endoscopic improvement (induction)—Trial running · NCT0757785613.1% vs 6.3%+6.8 vs placebo600 mg IV Q4W · wk 12 · n 61NCT02589665
2 other results
  • 30.6% vs 6.3% 200 mg IV Q4W · wk 12 · n 62 · Phase 2 · secondary NCT02589665
  • 23.8% vs 6.3% 50 mg IV Q4W · wk 12 · n 63 · Phase 2 · secondary NCT02589665
Corticosteroid-free remission (maintenance)—Trial running · NCT07577856—Not posted · NCT05784246

Clinical remission (induction)

JNJ-78934804
—Trial running · NCT07577856
mirikizumab
24.2% vs 13.3%+10.9 vs placebo300 mg IV Q4W · wk 12 · n 868NCT03518086
3 other results
  • 11.5% vs 4.8% 600 mg IV Q4W · wk 12 · n 61 · Phase 2 · primary NCT02589665
  • 22.6% vs 4.8% 200 mg IV Q4W · wk 12 · n 62 · Phase 2 · primary NCT02589665
  • 15.9% vs 4.8% 50 mg IV Q4W · wk 12 · n 63 · Phase 2 · primary NCT02589665

Clinical remission (maintenance)

JNJ-78934804
—Trial running · NCT07577856
mirikizumab
49.9% vs 25.1%+24.8 vs placebo200 mg SC · wk 40 · n 365NCT03524092

Clinical response (induction)

JNJ-78934804
—Trial running · NCT07577856
mirikizumab
63.5% vs 42.2%+21.3 vs placebo300 mg IV Q4W · wk 12 · n 868NCT03518086
3 other results
  • 49.2% vs 20.6% 600 mg IV Q4W · wk 12 · n 61 · Phase 2 · secondary NCT02589665
  • 59.7% vs 20.6% 200 mg IV Q4W · wk 12 · n 62 · Phase 2 · secondary NCT02589665
  • 41.3% vs 20.6% 50 mg IV Q4W · wk 12 · n 63 · Phase 2 · secondary NCT02589665

Endoscopic improvement (induction)

JNJ-78934804
—Trial running · NCT07577856
mirikizumab
13.1% vs 6.3%+6.8 vs placebo600 mg IV Q4W · wk 12 · n 61NCT02589665
2 other results
  • 30.6% vs 6.3% 200 mg IV Q4W · wk 12 · n 62 · Phase 2 · secondary NCT02589665
  • 23.8% vs 6.3% 50 mg IV Q4W · wk 12 · n 63 · Phase 2 · secondary NCT02589665

Corticosteroid-free remission (maintenance)

JNJ-78934804
—Trial running · NCT07577856
mirikizumab
—Not posted · NCT05784246
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JNJ-78934804: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. JNJ-78934804: 0 of 4 rows · mirikizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricmirikizumab
Dropout rate
—300 mg IVa
NCT03524092 · Phase 3
show 30 more results
—300 mg IV
NCT03524092 · Phase 3
—300 mg IV
NCT03524092 · Phase 3
—300 mg IV
NCT03524092 · Phase 3
—200 mg SC
NCT03524092 · Phase 3
11.5%200 mg SC
NCT03524092 · Phase 3
—200 mg SC
NCT03524092 · Phase 3
—200 mg SC
NCT03524092 · Phase 3
—300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
4.1%300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
7.2%300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
9.9%300 mg
NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
0%300 mg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—300 mg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—300 mg IV / 200 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—200 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—100 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
0%10 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV / 100 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV / 50 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—5 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—5 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—200 mg SC Q12W
NCT02589665 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
6.6%600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.2%200 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—50 mg Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—300 mg IVa
NCT03524092 · Phase 3
show 30 more results
—300 mg IV
NCT03524092 · Phase 3
—300 mg IV
NCT03524092 · Phase 3
—300 mg IV
NCT03524092 · Phase 3
—200 mg SC
NCT03524092 · Phase 3
7.7%200 mg SC
NCT03524092 · Phase 3
—200 mg SC
NCT03524092 · Phase 3
—200 mg SC
NCT03524092 · Phase 3
—300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
1.6%300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
1.6%300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
1.2%300 mg
NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—300 mg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—300 mg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—300 mg IV / 200 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—200 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—100 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV / 100 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV / 50 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—5 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—5 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—200 mg SC Q12W
NCT02589665 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.3%600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.2%200 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
—50 mg Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
Serious AEs
5.2%300 mg IVa
NCT03524092 · Phase 3
show 30 more results
6.1%300 mg IV
NCT03524092 · Phase 3
3.3%300 mg IV
NCT03524092 · Phase 3
16.7%300 mg IV
NCT03524092 · Phase 3
3.3%200 mg SC
NCT03524092 · Phase 3
13.5%200 mg SC
NCT03524092 · Phase 3
3.3%200 mg SC
NCT03524092 · Phase 3
9.1%200 mg SC
NCT03524092 · Phase 3
2.8%300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
8%300 mg IV Q4W
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
2.9%300 mg
NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
0%300 mg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
9.1%300 mg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—300 mg IV / 200 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—200 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—100 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
0%10 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
40%10 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV / 100 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
—10 mg/kg IV / 50 mg SC
NCT04004611 · Phase 2 · registry result, not featured evidence
0%5 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
0%5 mg/kg IV
NCT04004611 · Phase 2 · registry result, not featured evidence
4.4%200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
4.3%200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
2.2%200 mg SC Q12W
NCT02589665 · Phase 2 · registry result, not featured evidence
5.2%1000 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.1%600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
5%600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.2%200 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
0%50 mg Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
300 mg IVa
arthralgia 3.3% (placebo 4.2%)
nasopharyngitis 3.3% (placebo 5.7%)
headache 1.7% (placebo 1%)
NCT03524092 · Phase 3
show 24 more results
300 mg IV
upper respiratory tract infection 9.1% (placebo 2.6%)
anaemia 6.1% (placebo 4.7%)
covid-19 6.1% (placebo 2.1%)
NCT03524092 · Phase 3
300 mg IV
anaemia 5.6% (placebo 4.7%)
headache 5.6% (placebo 1%)
arthralgia 3.3% (placebo 4.2%)
NCT03524092 · Phase 3
300 mg IV
covid-19 8.3% (placebo 2.1%)
electrolyte imbalance 8.3% (placebo 0%)
haemorrhoids 8.3% (placebo 1.6%)
NCT03524092 · Phase 3
200 mg SC
nasopharyngitis 7.2% (placebo 5.7%)
arthralgia 6.7% (placebo 4.2%)
colitis ulcerative 6.7% (placebo 18.2%)
NCT03524092 · Phase 3
200 mg SC
upper respiratory tract infection 15.4% (placebo 2.6%)
covid-19 11.5% (placebo 2.1%)
abdominal pain 7.7% (placebo 2.1%)
NCT03524092 · Phase 3
200 mg SC
arthralgia 7% (placebo 4.2%)
nasopharyngitis 5.2% (placebo 5.7%)
headache 4.8% (placebo 1%)
NCT03524092 · Phase 3
200 mg SC
uterine leiomyoma 14.3% (placebo 0%)
upper respiratory tract infection 12.1% (placebo 2.6%)
anorectal polyp 6.1% (placebo 1%)
NCT03524092 · Phase 3
300 mg IV Q4W
anaemia 3.2% (placebo 5.6%)
colitis ulcerative 0% (placebo 0%)
upper respiratory tract infection 0% (placebo 0%)
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
300 mg IV Q4W
upper respiratory tract infection 12% (placebo 0%)
anaemia 6.4% (placebo 5.6%)
colitis ulcerative 2.4% (placebo 0%)
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
300 mg
any event 7%
any event 6.4%
any event 5.8%
NCT05767021 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
300 mg IV
rash 18.2%
dysmenorrhoea 16.7%
arthralgia 9.1%
NCT04004611 · Phase 2 · registry result, not featured evidence
300 mg IV
injection site pain 27.3%
asymptomatic covid-19 18.2%
covid-19 18.2%
NCT04004611 · Phase 2 · registry result, not featured evidence
10 mg/kg IV
anaemia 20%
covid-19 20%
pollakiuria 20%
NCT04004611 · Phase 2 · registry result, not featured evidence
10 mg/kg IV
covid-19 40%
anaemia 20%
dyspepsia 20%
NCT04004611 · Phase 2 · registry result, not featured evidence
5 mg/kg IV
headache 30%
pyrexia 20%
abdominal pain upper 10%
NCT04004611 · Phase 2 · registry result, not featured evidence
5 mg/kg IV
headache 30%
covid-19 20%
injection site pain 20%
NCT04004611 · Phase 2 · registry result, not featured evidence
200 mg SC Q4W
nasopharyngitis 20.6% (placebo 9.5%)
colitis ulcerative 10.3% (placebo 9.5%)
back pain 8.8% (placebo 0%)
NCT02589665 · Phase 2 · registry result, not featured evidence
200 mg SC Q4W
arthralgia 12.8% (placebo 0%)
nasopharyngitis 12.8% (placebo 9.5%)
headache 10.6% (placebo 4.8%)
NCT02589665 · Phase 2 · registry result, not featured evidence
200 mg SC Q12W
nasopharyngitis 17.4% (placebo 9.5%)
colitis ulcerative 15.2% (placebo 9.5%)
influenza 8.7% (placebo 0%)
NCT02589665 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
nasopharyngitis 7.3% (placebo 9.5%)
dry skin 1% (placebo 0%)
abdominal discomfort 0% (placebo 0%)
NCT02589665 · Phase 2 · registry result, not featured evidence
600 mg IV Q4W
nasopharyngitis 15.6% (placebo 9.5%)
influenza 9.4% (placebo 0%)
dry skin 6.3% (placebo 0%)
NCT02589665 · Phase 2 · registry result, not featured evidence
600 mg IV Q4W
nasopharyngitis 8.3% (placebo 9.5%)
headache 6.7% (placebo 4.8%)
nausea 5% (placebo 6.3%)
NCT02589665 · Phase 2 · registry result, not featured evidence
200 mg IV Q4W
nasopharyngitis 4.8% (placebo 9.5%)
anaemia 3.2% (placebo 4.8%)
nausea 3.2% (placebo 6.3%)
NCT02589665 · Phase 2 · registry result, not featured evidence
50 mg Q4W
nasopharyngitis 7.9% (placebo 9.5%)
anaemia 6.3% (placebo 4.8%)
headache 4.8% (placebo 4.8%)
NCT02589665 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 27 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

mirikizumab

Clinical Remission 49.9% (n=365) vs 25.1% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
Endoscopic Remission 58.6% (n=365) vs 29.1% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
show 2 more results
14.9% (n=47) vs 7.7% (n=13) placebo @ 52wk200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
28.3% (n=46) vs 7.7% (n=13) placebo @ 52wk200 mg SC Q12W
NCT02589665 · Phase 2 · registry result, not featured evidence
Histologic Remission 48.5% (n=365) vs 24.6% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
Symptomatic Remission 71% (n=365) vs 39.7% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
show 2 more results
76.6% (n=47) vs 53.8% (n=13) placebo @ 52wk200 mg SC Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
65.2% (n=46) vs 53.8% (n=13) placebo @ 52wk200 mg SC Q12W
NCT02589665 · Phase 2 · registry result, not featured evidence
Endoscopic 72.6% (n=365) vs 40.8% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
Clinical Response 80.3% (n=365) vs 49.2% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
IBDQ 49.75 vs 24.51 placebo score @ 40wk200 mg SC
absolute change · score
Maintenance
NCT03524092 · Phase 3
Urgency NRS -3.8 vs -2.74 placebo score @ 40wk200 mg SC
absolute change · score
Maintenance
NCT03524092 · Phase 3
UC Hospitalization 0% (n=365) vs 1.1% (n=179) placebo @ 40wk200 mg SC
responder rate · % of participants
Maintenance
NCT03524092 · Phase 3
Clinical Remission 24.2% (n=868) vs 13.3% (n=294) placebo @ 12wk300 mg IV Q4W
responder rate · % of participants
Induction
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 3 more results
11.5% (n=61) vs 4.8% (n=63) placebo @ 12wk600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
22.6% (n=62) vs 4.8% (n=63) placebo @ 12wk200 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
15.9% (n=63) vs 4.8% (n=63) placebo @ 12wk50 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
Clinical Response 63.5% (n=868) vs 42.2% (n=294) placebo @ 12wk300 mg IV Q4W
responder rate · % of participants
Induction
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 3 more results
49.2% (n=61) vs 20.6% (n=63) placebo @ 12wk600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
59.7% (n=62) vs 20.6% (n=63) placebo @ 12wk200 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
41.3% (n=63) vs 20.6% (n=63) placebo @ 12wk50 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
Endoscopic Remission 36.3% (n=868) vs 21.1% (n=294) placebo @ 12wk300 mg IV Q4W
responder rate · % of participants
Induction
NCT03518086 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 3 more results
1.6% (n=61) vs 1.6% (n=63) placebo @ 12wk600 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.2% (n=62) vs 1.6% (n=63) placebo @ 12wk200 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence
3.2% (n=63) vs 1.6% (n=63) placebo @ 12wk50 mg IV Q4W
NCT02589665 · Phase 2 · registry result, not featured evidence

+ 30 further endpoints in the CSV export.

Crohn's Disease

Shared mechanism: IL-23 p19 · full Crohn's Disease pipeline

JNJ-78934804

Developed by Johnson & Johnson

Phase 3 in Crohn's DiseaseCo-antibody combination (guselkumab + golimumab, SC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07577843 (registry estimate)

No aligned efficacy figure on record for this race.

mirikizumab · Omvoh

Marketed by Eli Lilly

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT03926130 · Phase 3 · completed

Randomized, triple-masked, placebo-controlled, adequately powered (n=1158 overall, ~778 in the placebo/mirikizumab primary comparison), with hard endoscopic (SES-CD response) and clinical remission co-primary endpoints, both meeting statistical significance (p<0.000001) favoring mirikizumab over placebo.

Next expected readout: September 2027 · NCT06997965 (registry estimate)

Reported efficacy

Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52); Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) (Week 12 to Week 52): Placebo 9.0% (95% CI 5.1-13.0) vs Mirikizumab 38.0% (95% CI 34.0-42.0); p=<0.000001 (Placebo vs Mirikizumab) (met)

Result source: NCT03926130

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointJNJ-78934804mirikizumab
Clinical remission (induction)—Trial running · NCT0757784337.7% vs 25.1%+12.6 vs placebowk 12 · n 579NCT03926130
Endoscopic response (induction)—Trial running · NCT0757784332.5% vs 12.6%+19.9 vs placebowk 12 · n 579NCT03926130
3 other results
  • 43.8% vs 10.9% 1000 mg IV Q4W · wk 12 · n 64 · Phase 2 · primary NCT02891226
  • 37.5% vs 10.9% 600 mg IV Q4W · wk 12 · n 32 · Phase 2 · primary NCT02891226
  • 25.8% vs 10.9% 200 mg IV Q4W · wk 12 · n 31 · Phase 2 · primary NCT02891226
Clinical remission (maintenance)—Trial running · NCT0757784354.1% vs 19.6%+34.5 vs placebowk 52 · n 579NCT03926130
Endoscopic response (maintenance)—Trial running · NCT0757784348.4% vs 9%+39.4 vs placebowk 52 · n 579NCT03926130

Clinical remission (induction)

JNJ-78934804
—Trial running · NCT07577843
mirikizumab
37.7% vs 25.1%+12.6 vs placebowk 12 · n 579NCT03926130

Endoscopic response (induction)

JNJ-78934804
—Trial running · NCT07577843
mirikizumab
32.5% vs 12.6%+19.9 vs placebowk 12 · n 579NCT03926130
3 other results
  • 43.8% vs 10.9% 1000 mg IV Q4W · wk 12 · n 64 · Phase 2 · primary NCT02891226
  • 37.5% vs 10.9% 600 mg IV Q4W · wk 12 · n 32 · Phase 2 · primary NCT02891226
  • 25.8% vs 10.9% 200 mg IV Q4W · wk 12 · n 31 · Phase 2 · primary NCT02891226

Clinical remission (maintenance)

JNJ-78934804
—Trial running · NCT07577843
mirikizumab
54.1% vs 19.6%+34.5 vs placebowk 52 · n 579NCT03926130

Endoscopic response (maintenance)

JNJ-78934804
—Trial running · NCT07577843
mirikizumab
48.4% vs 9%+39.4 vs placebowk 52 · n 579NCT03926130
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JNJ-78934804: no structured comparison results are available for Crohn's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. JNJ-78934804: 0 of 4 rows · mirikizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricmirikizumab
Dropout rate
11.1%Mirikizumaba
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 16 more results
33.3%Mirikizumab (Adolescents)
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
6.3%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
12.5%600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
6.5%200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.7%Mirikizumaba
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 16 more results
0%Mirikizumab (Adolescents)
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
9.4%600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
3.2%200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
—200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
Serious AEs
10.3%Mirikizumaba
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 16 more results
0%Mirikizumab (Adolescents)
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
0%300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
4.3%300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
11%300 mg SC Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
3.1%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
10%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
15.3%1000 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
9.4%600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
0%200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
covid-19 16.3% (placebo 10%)
anaemia 6.8% (placebo 4.7%)
arthralgia 6.5% (placebo 4.7%)
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 16 more results
arthralgia 16.7% (placebo 4.7%)
covid-19 16.7% (placebo 10%)
crohn's disease 16.7% (placebo 10%)
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
300 mg SC Q4W
abdominal distension 0% (placebo 0%)
abdominal pain 0% (placebo 1.6%)
alanine aminotransferase increased 0% (placebo 0%)
NCT02891226 · Phase 2 · registry result, not featured evidence
300 mg SC Q4W
arthralgia 13% (placebo 4.7%)
nasopharyngitis 13% (placebo 1.6%)
headache 8.7% (placebo 3.1%)
NCT02891226 · Phase 2 · registry result, not featured evidence
300 mg SC Q4W
nasopharyngitis 18.4% (placebo 1.6%)
injection site reaction 13.2% (placebo 0%)
headache 11.8% (placebo 3.1%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
vitamin d deficiency 50% (placebo 0%)
abdominal distension 0% (placebo 0%)
abdominal pain 0% (placebo 1.6%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
crohn's disease 100% (placebo 9.4%)
respiratory tract infection viral 100% (placebo 1.6%)
abdominal distension 0% (placebo 0%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
abdominal distension 0% (placebo 0%)
abdominal pain 0% (placebo 1.6%)
alanine aminotransferase increased 0% (placebo 0%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
headache 10.9% (placebo 3.1%)
nasopharyngitis 6.3% (placebo 1.6%)
arthralgia 4.7% (placebo 4.7%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
headache 13% (placebo 3.1%)
epididymitis 9.1% (placebo 0%)
abdominal pain 8.7% (placebo 1.6%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
headache 10% (placebo 3.1%)
nasopharyngitis 10% (placebo 1.6%)
anaemia 6.7% (placebo 1.6%)
NCT02891226 · Phase 2 · registry result, not featured evidence
1000 mg IV Q4W
anaemia 8.5% (placebo 1.6%)
fatigue 6.8% (placebo 4.7%)
headache 6.8% (placebo 3.1%)
NCT02891226 · Phase 2 · registry result, not featured evidence
600 mg IV Q4W
pyrexia 9.4% (placebo 1.6%)
weight increased 9.4% (placebo 0%)
abdominal distension 6.3% (placebo 0%)
NCT02891226 · Phase 2 · registry result, not featured evidence
600 mg IV Q4W
vulvovaginal mycotic infection 25% (placebo 2.8%)
anal incontinence 11.1% (placebo 0%)
anxiety 11.1% (placebo 1.6%)
NCT02891226 · Phase 2 · registry result, not featured evidence
200 mg IV Q4W
abdominal distension 0% (placebo 0%)
abdominal pain 0% (placebo 1.6%)
alanine aminotransferase increased 0% (placebo 0%)
NCT02891226 · Phase 2 · registry result, not featured evidence
200 mg IV Q4W
alanine aminotransferase increased 6.5% (placebo 0%)
anaemia 6.5% (placebo 1.6%)
aspartate aminotransferase increased 6.5% (placebo 0%)
NCT02891226 · Phase 2 · registry result, not featured evidence
200 mg IV Q4W
abdominal pain 11.1% (placebo 1.6%)
anaemia 11.1% (placebo 1.6%)
arthralgia 11.1% (placebo 4.7%)
NCT02891226 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 15 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

mirikizumab

Clinical Response and Endoscopic Response Composite 38% (n=579) vs 9% (n=199) placebo @ 52wk
responder rate · % of participants
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response and Clinical Remission Composite 45.4% (n=579) vs 19.6% (n=199) placebo @ 52wk
responder rate · % of participants
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more result
45.4% (n=579) vs 19.6% (n=199) placebo @ 52wk
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Endoscopic 43.8% (n=64) vs 10.9% (n=64) placebo @ 12wk1000 mg IV Q4W
responder rate · % of participants
NCT02891226 · Phase 2 · registry result, not featured evidence
show 4 more results
37.5% (n=32) vs 10.9% (n=64) placebo @ 12wk600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
25.8% (n=31) vs 10.9% (n=64) placebo @ 12wk200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
32.5% (n=579) vs 12.6% (n=199) placebo @ 12wk
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
48.4% (n=579) vs 9% (n=199) placebo @ 52wk
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Remission 37.7% (n=579) vs 25.1% (n=199) placebo @ 12wk
responder rate · % of participants
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more result
54.1% (n=579) vs 19.6% (n=199) placebo @ 52wk
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Endoscopic Remission 20.3% (n=64) vs 1.6% (n=64) placebo @ 12wk1000 mg IV Q4W
responder rate · % of participants
NCT02891226 · Phase 2 · registry result, not featured evidence
show 4 more results
15.6% (n=32) vs 1.6% (n=64) placebo @ 12wk600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
6.5% (n=31) vs 1.6% (n=64) placebo @ 12wk200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
10.9% (n=579) vs 4% (n=199) placebo @ 12wk
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
17.6% (n=579) vs 7% (n=199) placebo @ 12wk
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Urgency NRS -2.44 vs -1.58 placebo score @ 12wk
absolute change · score
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more result
-3.24 vs -1.23 placebo score @ 52wk
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response and Endoscopic Remission Composite 15.9% (n=579) vs 2% (n=199) placebo @ 52wk
responder rate · % of participants
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more result
23.5% (n=579) vs 4% (n=199) placebo @ 52wk
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response and Corticosteroid-free Clinical Remission Composite 43.7% (n=579) vs 18.6% (n=199) placebo @ 52wk
responder rate · % of participants
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response and EIM Resolution Composite 43.2% (n=132) vs 14.6% (n=41) placebo @ 52wk
responder rate · % of participants
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response and Fistula Reduction Composite 21.1% (n=38) vs 16.7% (n=18) placebo @ 52wk
responder rate · % of participants
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
IBDQ Total 43.82 vs 15.9 placebo score @ 52wk
absolute change · score
NCT03926130 · Phase 3 · monotherapy · Crohn's Disease · phase 3
PRO-2 Remission 21.9% (n=64) vs 6.3% (n=64) placebo @ 12wk1000 mg IV Q4W
responder rate · % of participants
NCT02891226 · Phase 2 · registry result, not featured evidence
show 2 more results
28.1% (n=32) vs 6.3% (n=64) placebo @ 12wk600 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence
12.9% (n=31) vs 6.3% (n=64) placebo @ 12wk200 mg IV Q4W
NCT02891226 · Phase 2 · registry result, not featured evidence

+ 4 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JNJ-78934804's landscape · mirikizumab's landscape